6/18/2021 7:41:58 AM
Diffusion Reminds Stockholders To Vote On Proposals Listed In Proxy Statement
3/18/2021 7:07:41 AM
Diffusion Doses First Participants In TCOM Study
2/11/2021 10:05:34 PM
Diffusion Pharma Increases Bought Deal Offering Of Common Stock To $30 Mln
10/19/2020 8:08:56 AM
Diffusion Pharma Appoints Chris Galloway As Chief Medical Officer
9/10/2020 8:10:30 AM
Diffusion Doses First Two Patients With TSC In COVID-19 Clinical Trial
7/27/2020 8:21:49 AM
Diffusion Gets FDA Guidance For International Phase 1b/2b COVID-19 Clinical Program With TSC
6/1/2020 8:09:00 AM
Diffusion Regains Compliance With NASDAQ Minimum Bid Price Requirement
5/26/2020 8:06:39 AM
Diffusion Receives Accelerated Response From FDA To PIND Meeting Request
4/1/2020 8:15:59 AM
Diffusion Evaluates Trans Sodium Crocetinate Against ARDS In COVID-19 Patients
2/7/2020 8:38:43 AM
Diffusion Pharmaceuticals Secures European Patent Related Compositions Of TSC